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Patrick Gilon 1,*ABSTRACT
Objective: Sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2i), or gliflozins, are anti-diabetic drugs that lower glycemia by promoting
glucosuria, but they also stimulate endogenous glucose and ketone body production. The likely causes of these metabolic responses are
increased blood glucagon levels, and decreased blood insulin levels, but the mechanisms involved are hotly debated. This study verified whether
or not SGLT2i affect glucagon and insulin secretion by a direct action on islet cells in three species, using multiple approaches.
Methods: We tested the in vivo effects of two selective SGLT2i (dapagliflozin, empagliflozin) and a SGLT1/2i (sotagliflozin) on various biological
parameters (glucosuria, glycemia, glucagonemia, insulinemia) in mice. mRNA expression of SGLT2 and other glucose transporters was assessed
in rat, mouse, and human FACS-purified a- and b-cells, and by analysis of two human islet cell transcriptomic datasets. Immunodetection of
SGLT2 in pancreatic tissues was performed with a validated antibody. The effects of dapagliflozin, empagliflozin, and sotagliflozin on glucagon
and insulin secretion were assessed using isolated rat, mouse and human islets and the in situ perfused mouse pancreas. Finally, we tested the
long-term effect of SGLT2i on glucagon gene expression.
Results: SGLT2 inhibition in mice increased the plasma glucagon/insulin ratio in the fasted state, an effect correlated with a decline in glycemia.
Gene expression analyses and immunodetections showed no SGLT2 mRNA or protein expression in rodent and human islet cells, but moderate
SGLT1 mRNA expression in human a-cells. However, functional experiments on rat, mouse, and human (29 donors) islets and the in situ perfused
mouse pancreas did not identify any direct effect of dapagliflozin, empagliflozin or sotagliflozin on glucagon and insulin secretion. SGLT2i did not
affect glucagon gene expression in rat and human islets.
Conclusions: The data indicate that the SGLT2i-induced increase of the plasma glucagon/insulin ratio in vivo does not result from a direct action
of the gliflozins on islet cells.
 2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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SGLT2 inhibitors (SGLT2i), called gliflozins, decrease glycemia by
blocking glucose reabsorption by the kidney, thus promoting glucosuria.
They are extensively used to treat diabetes and exert other beneficial
effects such as improvement of insulin sensitivity and b-cell function,
cardiorenal protection, and weight loss [1e7]. SGLT2i-induced gluco-
suria is associated with metabolic responses, including an increase in
lipolysis, endogenous glucose, and ketone body production [3,8,9]. The
paradoxical increase in endogenous glucose production (EGP) is a
concern, as it diminishes the efficacy of glucosuria-stimulating therapy
[3]. An additional drawback of SGLT2i is the increased incidence of
ketoacidosis and the emergence of rare euglycemic diabetic ketoaci-
dosis [10e14]. The rise in ketone body levels results from their
increased production rather than decreased renal clearance [15]. The
potential causes of these metabolic responses are the SGLT2i-mediated
increase in blood glucagon levels and decrease in blood insulin levels
[3,8,10], but themechanisms by which gliflozins increase glucagonemia
are highly contested [7,16e18]. Some studies have suggested that
gliflozins act directly on a-cells that express SGLT2 [19e22]. Others
suggested that a-cells express SGLT1 but not SGLT2 and that gliflozins
that do not display an exclusive selectivity for SGLT2 stimulate glucagon
release by inhibiting SGLT1 [23,24]. An indirect control of glucagon
release by gliflozins via d-cells has also been proposed [25]. However,
these hypotheses are contested by studies suggesting no SGLT2
expression in a-cells and no effect of gliflozins on glucagon release
[17,26] or an inhibition of glucagon release by gliflozins [22,27]. As
glucagon and somatostatin strongly influence b-cells, gliflozins might
indirectly control insulin secretion, but several reports do not support this
mechanism [11,14,19,26,28].
In the present study, we tested the possibility that SGLT2i affect
glucagon and insulin secretion via a direct action on islet cells. To
identify potential interspecies differences that might explain the
controversies, this study was conducted on three species: rats, mice,
and humans. To increase the strength of our analysis, we used
multiple approaches. 1) We studied mRNA expression of SGLT2 and
other glucose transporters in fluorescence-activated cell sorting-
(FACS-)purified a- and b-cells. 2) We analyzed two human islet cell
transcriptomic datasets. 3) We performed immunodetections of
SGLT2 in pancreatic tissues with a carefully validated antibody. 4) We
tested the effects of dapagliflozin, empagliflozin (two SGLT2i), and
sotagliflozin (a dual SGLT1/2i) on glucagon and insulin secretion from
isolated rat, mouse, and human islets and from the in situ perfused
mouse pancreas. 5) We verified the effects of the gliflozins in vivo in




The experiments were approved by the committees for animal welfare
(2014/UCL/MD/016 and 2018/UCL/MD/18) and human islets (2017/
12JUL/369) at the Université Catholique de Louvain and followed the
regulatory conditions of Boehringer Ingelheim’s corporate policy in
accordance with German legislation.
2.2. Models and tissue preparation
2.2.1. Rodent strains and islet preparation
Wistar-Han rats and C57BL/6N mice (6e12 months) were used for all
experiments, except for gene expression, which was conducted using2 MOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. TGlu-Venus [29] and RIPYY mice [30]. Islets were isolated by collage-
nase and cultured overnight in RPMI 1640 medium containing 11 mM
(rat) or 7 mM (mouse) glucose and 10% FBS.
2.2.2. Human islets
The origin and characteristics of the human islet preparations are
listed in Supplementary Table S1. After shipment, the islets were
cultured for 2e17 days (mean: 5.5 d; median: 5 d) in RPMI 1640
medium containing 5 mM glucose and 10% FBS or PIM medium
(Prodo Labs).
2.3. Fluorescence-activated cell sorting and gene expression
measurements
2.3.1. FACS
Dispersed islet cells were FACS-sorted using methods adapted to the
different species (Supplementary Figure S1).
2.3.2. cDNA preparation
RNA was extracted using Dynabead-oligo dT or TriPure and reverse
transcribed into cDNA.
2.3.3. qPCR
TaqMan probes and SYBR Green were used. See Supplementary
Table S2 for probe sets and primers. Changes in gene mRNA levels
normalized to those of reference genes (ACTB, Gapdh, TBP, or RPLP0)
are shown as 2DCt.
2.4. Single-cell RNA-Seq analysis from public data
We downloaded two pre-processed single-cell datasets [31,32] from
ArrayExpress (E-MTAB-5061) and the EBI Single-Cell Expression Atlas
(E-GEOD-81547) (analysis pipeline details in the respective entries).
Apart from the TPM matrix, we used inferred cell type annotation
provided with the respective entries to visualize the gene expression
per cell type.
2.5. 14C-aMG uptake experiments and Western blotting analysis of
SGLT2
14C-aMG uptake experiments were conducted as previously described
[33]. The anti-SGLT2 antibody was characterized by Western blotting
analysis using total membrane extracts of lysates from human islets
and kidneys, and HEK293 cells expressing SGLT2 or not. Western
blotting analysis and PNGaseF treatment were performed as previously
described [34].
2.6. Immunodetection of SGLT2 and islet hormones
Pancreatic and kidney tissues of human, mouse, and rat origin
were fixed in 4% paraformaldehyde prior to paraffin embedding.
Three-mm thick sections were processed for multiplex immuno-
fluorescence. Briefly, sections were sequentially incubated for
30 min at room temperature with primary antibodies
(Supplementary Table S2) and then for 30 min at room temperature
with an Opal Polymer Anti-Mouse and Rabbit HRP Kit (PerkinElmer).
Immunofluorescent signal was visualized using the OPAL TSA dye
520, 570, 650 and 690.
2.7. In vivo experiments
Drugs (dapagliflozin, empagliflozin, and sotagliflozin, 1e10 mg/kg BW)
or vehicle (DMSO) were administered by oral gavage to mice either
once or one dose during 3 consecutive days. ELISA kits were used to
assay plasma glucagon (Mercodia) and insulin (Crystal Chem).his is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
www.molecularmetabolism.com
Figure 1: Gliflozins increase glucosuria and induce an increase in the glucagonemia/insulinemia ratio that correlates with a decline in glycemia in fasted mice. (A-D)
Gliflozins efficiently increase glucosuria. (A) Schematic design of gliflozin treatment. C57BL/6N male mice (n ¼ 6/group) housed in metabolic cages received by oral gavage vehicle
(0.1% DMSO), dapagliflozin (Dapa), empagliflozin (Empa), or sotagliflozin (Sota) (1 mg/kg body weight [BW] for each gliflozin). Blood glucose (B) was measured right before oral
gavage and 16 h later. D blood glucose between these two time points was calculated as the percentage change (C). Glucosuria (D) was measured in urine collected during this
16-h period. Graphs in panels C-D show individual data and means  SE. *p < 0.05 and ***p < 0.001, paired t-test for comparison between 0 h and 16 h and unpaired t-test for
comparison between vehicle and treatment. (E) Schematic design of dapagliflozin treatment. C57BL/6N male mice (n ¼ 12e14/group) housed in regular cages were fasted
overnight for 16 h and received by oral gavage, right after fasting, vehicle (0.6e1% DMSO) or dapagliflozin 1 or 10 mg/kg BW. Blood glucose (F) was measured before fasting, after
fasting right before vehicle or dapagliflozin administration, and 1 h later. D blood glucose calculated as the percentage change before and 1 h after oral gavage is illustrated in the
right panel. Glucagonemia (G), insulinemia (H), and the glucagonemia/insulinemia ratio (I) were measured 1 h after oral gavage. (J) Correlation between the changes in blood
glucose (percentage taken from the right panel in F) and the glucagonemia/insulinemia ratio (taken from I). R2 ¼ 0.4009. Graphs in panels FeI show individual data and
means  SE. **p < 0.01 and ***p < 0.001 for comparisons between treatments, ordinary one-way ANOVA followed by Tukey’s test for multiple comparisons.
MOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 2: Gliflozins do not directly affect glucagon and insulin secretion in rodents. (A) Islets from Wistar-Han rats (10 islets/100 ml medium) were incubated for 1 h in a
medium containing 1 mM glucose and various test agents including arginine (10 mM), KCl (60 mM), adrenaline (10 mM), empagliflozin (1 or 10 mM), or dapagliflozin (1 or 10 mM).
Values are means  SE for 5e6 batches of islets. *p < 0.05, **p < 0.01, and ***p < 0.001 for comparisons between treatments and control (G1) , ordinary one-way ANOVA
followed by Fisher’s LSD test for multiple comparison. The trend for glucagon secretion increase induced by 10 mM dapagliflozin was not significant (p ¼ 0.504) (BeF) Pancreas
from C57BL/6N mice were perfused in situ with a solution containing a 2 mM mixture of various amino acids present at the following concentrations, which mimics physiological
concentrations (in mM): 0.4 alanine, 0.5 glutamine, 0.2 lysine, 0.25 glycine, 0.15 leucine, 0.25 valine, 0.15 threonine, and 0.1 serine. The glucose (G) concentration was changed
between 7 or 15 and 2 mM, and dapagliflozin (Dapa, 1 or 10 mM), empagliflozin (Empa, 1 mM), sotagliflozin (Sota, 1 mM), and arginine (Arg, 10 mM) were applied when indicated.
Traces are means  SE of 3e8 experiments with different mice. Graphs on the right of F are scatter-dot plots with bar graphs showing individual data and means  SE of the
average glucagon and insulin secretions calculated from the experiments shown on the left. Because glucagon secretion displayed important spontaneous time-dependent
changes, the mean secretion in the presence of a test agent (dapagliflozin or arginine) was compared to the mean secretion integrated over the control period before and af-
ter the application of the test agent (G7 or G2 vs G7 or G2 þ dapagliflozin 1 mM: mean of 20e36 and 60e80 min vs mean of 40e56 min; G7 or G2 vs G7 or G2 þ dapagliflozin
10 mM: mean of 60e80 and 108e128 min vs mean of 84e104 min; and G7 and G2 vs G7 or G2 þ arginine 10 mM: mean of 108e128 and 156e168 min vs mean of 132e
148 min). *p < 0.05, and **p < 0.01, paired t-test for comparison between different conditions.
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These experiments were performed with rat and human islets (10
islets/100 mL medium). The medium contained (in mM): 137 NaCl, 5.4
KCl, 1.3 CaCl2, 0.81 MgSO4, 0.34 NaH2PO4, 0.44 KH2HPO4þ 1 mg/mL
BSA, and was at pH 7.4. Islets were maintained for 30 min in a me-
dium containing 25 (rat) or 11.1 mM (human) glucose before being
transferred in a medium containing 1 mM glucose and the respective
treatments. One hour later, glucagon was determined using a Fluo-
rescent EIA Kit (Phoenix Pharmaceuticals).
2.8.2. Dynamic secretion experiments
Experiments on perifused mouse and human islets and perfused
mouse pancreas were performed as previously described [35]. The
medium contained (in mM): 124 NaCl, 4.8 KCl, 2.5 CaCl2, 1.2
MgCl2, 20 NaHCO3 þ 1 mg/mL BSA, and was at pH 7.4. Except
where otherwise indicated, it was supplemented with a 6 mM
mixture (for the perifused islets) or 2 mM mixture (for the perfused
pancreas) of amino acids (see figure legends). Insulin (home-made
assay) and glucagon (Merck Millipore) were measured by
radioimmunoassays.
2.9. Statistical methods
Statistical significance of differences between means was evaluated
by paired t-tests or one-way ANOVA followed by Tukey’s or Fisher’s
LSD test as described in the figure legends and results.
3. RESULTS
3.1. In vivo experiments
To verify the efficiency of the gliflozins used, dapagliflozin, empa-
gliflozin, sotagliflozin (1 mg/kg BW), or vehicle (DMSO) were
administered by oral gavage in mice maintained for 16 h in
metabolic cages and their urine was collected (Figure 1A). Glycemia
tended to decrease during this 16-h period but gliflozins did not
exacerbate this drop (Figure 1BeC). As expected, all of the gli-
flozins strongly increased glucosuria, whereas the vehicle had no
effect (Figure 1D).
In another series of experiments, we tested the effect of dapagliflozin
(1e10 mg/kg BW) on glucagonemia and insulinemia. Mice were fasted
for 16 h (a condition where glucagonemia is increased) before
receiving a single dose of either vehicle or gliflozin (Figure 1E) and their
blood was collected 1 h later. As expected, fasting significantly
decreased glycemia in all groups (Figure 1F). Dapagliflozin induced a
further decrease in glycemia 1 h later and significantly increased
glucagonemia and the glucagon/insulin ratio (without affecting insu-
linemia) (Figure 1FeJ). The glucagon/insulin ratio significantly corre-
lated with the decline in glycemia (Figure 1J). In a third experimental
series, gliflozins or vehicle were administered by oral gavage daily for 3
days to fed mice (Supplementary Figure S2A) and their blood was
collected 16 h later. Glycemia was unaltered across the 3 days
(Supplementary Figure S2B). Glucagonemia and insulinemia tended to
decrease (Supplementary Figures S2CeD), but this was not exacer-
bated by the gliflozins (Supplementary Figures S2CeD: right panels).
Moreover, none of the treatments affected the glucagon/insulin ratio
(Supplementary Figure S2E).
3.2. SGLT2 inhibitors do not affect glucagon and insulin secretion
We evaluated whether gliflozins control islet hormone secretion
directly.MOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. This is an open a
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Rat islets were incubated in the presence of 1 mM glucose to test the
effects of empagliflozin, dapagliflozin (1e10 mM), and other agents
used as controls on glucagon secretion. Although arginine, high Kþ,
and adrenaline significantly stimulated glucagon secretion, SGLT2i had
no significant effect (Figure 2A).
3.2.2. Mice
The in situ perfused pancreas was used as the closest model to the
in vivo situation. As commonly observed with this preparation [35e37],
glucagon secretion decreased with time. As it has been claimed that
the effect of gliflozins depends on the glucose concentration [19,20],
we tested different protocols at various glucose (G) concentrations.
Switching between 7 mM (G7) and 2 mM glucose (G2) (Figure 2BeE) or
between G15 and G2 (Figure 2E) or the addition of 10 mM arginine
(Figure 2F) strongly stimulated glucagon secretion. Dapagliflozin
(1e10 mM), empagliflozin (1 mM), or sotagliflozin (1 mM) did not affect
glucagon release and did not prevent the glucagonotropic effect of G2.
Parallel measurements of insulin showed that G7, G15, and arginine
stimulated insulin release (Figure 2BeF). In contrast, the gliflozins did
not affect insulin secretion.
3.2.3. Humans
All these experiments were conducted on isolated islets. During static
incubation experiments, glucagon secretion was lower at G11.1 than
G1 and markedly stimulated by arginine and high Kþ (Figure 3A).
However, neither empagliflozin nor dapagliflozin (10 mM) affected
glucagon release. During dynamic perifusion experiments, switching
from G10 to G0.5 strongly stimulated glucagon secretion and
inhibited insulin release (Figure 3BeH). Dapagliflozin (1e10 mM),
empagliflozin (1 mM), or sotagliflozin (1 mM) did not affect glucagon
or insulin release and did not prevent the glucagonotropic effect of
G0.5. The effect of the gliflozins was also tested at other glucose
concentrations (Figure 4). Increasing the glucose concentration from
4 to 15 mM inhibited glucagon secretion and strongly stimulated
insulin release (Figure 4AeC). In contrast, the gliflozins did not have
significant effects on secretion of either hormone. All experiments
described above were designed to test the effect of the gliflozins on
glucagon secretion and were performed in the presence of amino
acids that stimulate glucagon secretion. An additional series of ex-
periments was performed in the absence of amino acids using a
protocol that was designed to examine the potential effects of the
gliflozins on insulin release. Switching from G7 to G15 induced a
stimulation of insulin secretion that was reversed by the KATP channel
opener, diazoxide, but further stimulated by high Kþ (Figure 4DeG).
Elevating the glucose concentration from G7 to G15 or adding diaz-
oxide had no effect on glucagon release; this was expected, as the
glucagonostatic effect of glucose is known to be maximal at w G7
[38,39]. High Kþ stimulated glucagon release. However, none of the
gliflozins (1 mM) affected glucagon or insulin release.
3.3. SGLT2 mRNA is not expressed in a- and b-cells
3.3.1. Gene expression measurements by qPCR
Three different methods, adapted to each species, were used to
purify a- and b-cells by FACS (Supplementary Figure S1). The purity
of both populations was excellent for all species, as insulin and
glucagon mRNA were almost exclusively expressed in each of them
(Figure 5AeB, D-E, and J-K). In rats, SGLT2 (Slc5a2) mRNA was
absent in islet cells and in a series of other tissues except for kidney
tissue, where it was highly expressed (Figure 5C, Supplementaryccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 5
Figure 3: Gliflozins do not directly affect glucagon and insulin secretion from human islets. (A) Human islets (10 islets/100 ml medium) were incubated for 1 h in a medium
containing 1 or 11.1 mM glucose and various test agents including arginine (10 mM), KCl (60 mM), empagliflozin (10 mM), or dapagliflozin (10 mM). Values are means  SE for
7e8 batches of islets. **p < 0.01 and ***p < 0.001 for comparisons between treatments and control (G1), ordinary one-way ANOVA followed by Fisher’s LSD test for multiple
comparisons. (BeH) Human islets (200e300 islets/chamber) were perifused with a solution containing a 6 mM mixture of three amino acids present at the following con-
centrations (in mM): 2 alanine, 2 glutamine, and 2 arginine. The glucose (G) concentration was changed between 10 and 0.5 mM, and dapagliflozin (Dapa, 1 or 10 mM),
empagliflozin (Empa, 1 mM), and sotagliflozin (Sota, 1 mM) were applied when indicated. Traces are means  SE of 3e7 experiments with different preparations. Graphs on the
right of panels B-E are scatter-dot plots with bar graphs showing individual data and means  SE of the average glucagon and insulin secretions calculated from the experiments
shown on the left. Because glucagon secretion displayed spontaneous time-dependent changes, the mean secretion in the presence of the gliflozins was compared to the mean
secretion integrated over the control period before and after the application of the gliflozins (G10 vs G10 þ dapagliflozin or empagliflozin: mean of 20e36 and 76e108 min vs
mean of 40e72 min; G0.5 vs G0.5 þ dapagliflozin or empagliflozin: mean of 132e148 and 188e204 vs mean of 152e184 min; G10 vs G010 þ sotagliflozin: mean of 20e36
and 92e108 min vs mean of 40e68 min; and G0.5 vs G0.5 þ sotagliflozin: mean of 148e164 and 200e240 vs mean of 168e196 min). *p < 0.05 and **p < 0.01, paired t-
test for comparison between different conditions.
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Figure S3). In mice and humans, expression of glucose transporters
other than SGLT2 was also measured for comparison (Figure 5FeI
and L-O). In both species, SGLT2 mRNA was not detected in islet
cells, whereas it was highly expressed in the kidney. It was also
absent in a panel of other human tissues, except for a slight
expression in the spleen (Supplementary Figure S3). SGLT1 (Slc5a1)
mRNA was very poorly expressed in mouse and human b-cells, but
more expressed in a-cells from humans than from mice, and strongly
expressed in the duodenum (control tissue) of both species. GLUT1
(Slc2a1) and GLUT2 (Slc2a2) mRNA were more expressed in mouse
and human b- than in a-cells. As expected, GLUT2 was much more
expressed than GLUT1 in mouse b-cells, whereas the reverse was
found in human b-cells.
3.3.2. Single-cell RNA-Seq analyses
We conducted two analyses of human single-cell RNA-Seq data from
public domains (Figure 6 and Supplementary Figure S4). They
confirmed our qPCR experiments and showed a moderate expression
of SGLT1 in 25e50% of a-cells and no detectable expression of
SGLT2 in the vast majority of islet cells. A modest expression of SGLT2
was observed in only 0.5e2.5% of a-cells, regardless of the gender or
diabetic status (Figure 6CeD).
3.4. SGLT2 protein is not detectable in islet cells
3.4.1. Validation of the antibody
The anti-SGLT2 antibody was first validated on HEK293 cells
expressing (HEK293-hSGLT2) or not expressing SGLT2. qPCR exper-
iments confirmed that SGLT2 mRNA was not detected in HEK293 cells,
whereas it was highly expressed in HEK293-hSGLT2 cells and the
kidney (Figure 7A). Experiments based on the uptake of 14C-a-methyl-
D-glucopyranoside (aMG), a non-metabolizable glucose analogue
specifically transported by SGLTs, showed that only HEK293-hsSGLT2
took up 14C-aMG and that this uptake was fully prevented by empa-
gliflozin (EC50: 4.3 nM), the SGLT family inhibitor, phlorizin (EC50:
41 nM), and Naþ omission (Figure 7B).
In vivo, SGLT2 is highly glycosylated. We verified that the antibody
raised against a 46 amino acid sequence (208e253) corresponding to
an extracellular loop of human SGLT2 recognized equally well the
glycosylated and unglycosylated protein. Membrane extracts of lysates
from HEK293, HEK293-hSGLT2, and human kidney and islet cells were
either pretreated or not pretreated with PNGaseF, a deglycosylation
enzyme, before Western blotting. In keeping with the lack of SGLT2
mRNA expression in naïve HEK293 cells and islet cells, no band was
detected by the anti-SGLT2 antibody (Figure 7C). In contrast, a clear
band was observed in extracts from HEK293-hSGLT2 cells and the
kidney. As expected, removal of glycosylation residues by PNGaseF
induced a shift in the apparent molecular weight, but importantly, it did
not affect the ability of the antibody to detect SGLT2. Immunode-
tections of SGLT2 were then conducted on fixed cells (Figure 7D). They
revealed no signal in naïve HEK293 cells but a strong membrane la-
beling in HEK293-hSGLT2 cells, which indicated that the antibody
specifically recognized SGLT2 in the fixed cells.
3.4.2. Immunodetections of SGLT2 in kidney and pancreatic
sections
As expected, SGLT2 immunodetection showed a strong labeling
restricted to proximal tubules in the kidneys of rats, mice, and humans
(Figure 7E). Labeling was prevented by preincubation of the antibody
with an SGLT2 peptide (not shown). Immunodetections were con-
ducted on pancreatic sections including a total of 587 human, 305 rat,MOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.comand 158 mouse islets (including 73,957 islet cells from 3 pancreas/
species) (Figure 7F). b-, a-, and d-cells were identified by antibodies
against insulin, glucagon, and somatostatin, respectively. Immuno-
detection of SGLT2 on the same sections did not reveal any SGLT2
labeling in the three species. Pancreatic sections from patients with
type 1 and type 2 diabetes were also negative for SGLT2 (not shown,
n ¼ 3/group).
3.5. SGLT inhibition does not affect glucagon gene expression
Rat and human islets were treated for 24 h with 10 mM empagliflozin
or dapagliflozin in the presence of two different glucose concentrations
adapted to the species (G11 and G25 for rats and G5 and G15 for
humans; Figure 8). Neither SGLT2i affected glucagon gene expression
under any of the tested conditions.
4. DISCUSSION
We showed that SGLT2 inhibition in mice increases the plasma
glucagon/insulin ratio in the fasted state, an effect correlated with a
decline in glycemia. However, functional experiments on pancreatic
tissue from rats, mice, and humans did not reveal any direct effect of
SGLT1/2 inhibitors on glucagon and insulin secretion. Gene expression
analysis and immunodetection showed no detectable SGLT2 expres-
sion in the islet cells of all three species. However, we found modest
SGLT1 gene expression in human a-cells only. SGLT2 inhibition also
had no effect on glucagon gene expression. The data strongly suggest
that the increase in the plasma glucagon/insulin ratio induced by
SGLT1/2i in vivo does not result from a direct action of the gliflozins on
islet cells, but is likely secondary to their insulin-independent glucose-
lowering effects.
4.1. SGLT2 inhibition increases the plasma glucagon/insulin ratio
in the fasted state
The gliflozins (dapagliflozin, empagliflozin, and sotagliflozin) tested in
this study were very effective, as they strongly increased glucosuria.
Several reports have shown that gliflozins increase glucagonemia or
decrease insulinemia [3,8,14,19,23]. We replicated these observations
as administering dapagliflozin (1e10 mg/kg BW) to fasted mice pro-
duced, 1 h later, a dose-dependent increase in glucagonemia and the
plasma glucagon/insulin ratio. These changes correlated with a decline
in glycemia. One mg/kg BW of dapagliflozin induces a plasma Cmax of
w500 nM in mice [40], which is close to the plasma Cmax ofw400 nM
in humans who are receiving a therapeutic dose of 10 mg [41].
However, contrary to reports showing increased glucagonemia 6 h or
18 h after dapagliflozin administration [14,19], we did not find any
alteration in the glucagon/insulin ratio 16 h after three daily doses
(1 mg/kg BW) of dapagliflozin, empagliflozin, or sotagliflozin. This lack
of effect might be explained by the relatively rapid clearance of the
gliflozins [42,43].
4.2. SGLT2 is not expressed in islet cells of rats, mice, and
humans
We measured SGLT2 gene expression in FACS-purified populations of
a- and b-cells from rats, mice, and humans. In the three species,
SGLT2 expression was below detection levels in both a- and b-cells,
whereas it was highly expressed in the kidney. In mice and humans,
we also measured the gene expression of SGLT1. Interestingly, SGLT1
was barely detectable in mouse a- and b-cells, whereas it was well
expressed in human a-cells. Complementary analysis of two single-
cell RNA-Seq datasets confirmed our qPCR analysis, in agreement
with a recent study [17]. In particular, no expression of SGLT2 wasccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 7
Figure 4: Gliflozins do not directly affect glucagon and insulin secretion from human islets. (AeC) Human islets (w200e300 islets/chamber) were perifused with a
solution containing a 6 mM mixture of three amino acids present at the following concentrations (in mM): 2 alanine, 2 glutamine, and 2 arginine. The glucose (G) concentration was
changed between 4 and 15 mM, and dapagliflozin (Dapa, 1 mM), empagliflozin (Empa, 1 mM), and sotagliflozin (Sota, 1 mM) were applied when indicated. Traces are means  SE
of 3e6 experiments with different preparations. Graphs on the right of panels AeC are scatter-dot plots with bar graphs showing individual data and means  SE of the average
glucagon and insulin secretions calculated from the experiments shown on the left. The mean secretion in the presence of the gliflozins was compared to the mean secretion
integrated over the control period before and after the application of the gliflozins (G4 vs G4 þ gliflozin: mean of 20e52 and 88e120 min vs mean of 56e84 min; G15 vs
G15 þ gliflozin: mean of 148e160 and 196e228 vs mean of 164e192 min). In panel C, the trend in glucagon secretion increase induced by sotagliflozin in G4 was not significant
when comparing the mean of 20e52 min vs the mean of 56e84 min (p ¼ 0.0651). (D-G) Human islets (w300e400 islets/chamber) were perifused with an amino acid-free
solution. The glucose (G) concentration was changed between 7 and 15 mM, and vehicle (DMSO 0.002%), dapagliflozin (1 mM), empagliflozin (1 mM), sotagliflozin (1 mM),
diazoxide (Dz, 250 mM), and KCl (30 mM, K30) were added when indicated. Traces are means  SE of 3e6 experiments with different preparations. Graphs on the right of panels
D-G are scatter-dot plots with bar graphs showing individual data and means  SE of the average glucagon and insulin secretions calculated from the experiments shown on the
left. The mean secretion in the presence of vehicle or gliflozins was compared to the mean secretion integrated over the control period before and after the application of the test
agent (G7 vs G7 þ vehicle or gliflozin: mean of 20e48 and 76e104 min vs mean of 52e72 min; G15 vs G15 þ vehicle or gliflozin: mean of 120e140 and 168e196 vs mean of
144e164 min; and G15 Dz vs G15 K30: mean of 212e220 min vs mean of 240e248 min). *p < 0.05, **p < 0.01 and ***p < 0.001, paired t-test for comparison between
different conditions.
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Figure 5: The SGLT2 gene is not expressed in rat, mouse, or human pancreatic islet cells. (AeB) Insulin (Ins) and glucagon (Gcg) gene expression in rat FAC-sorted a- and
b-cells and pancreatic islets normalized to Rplp0. (C) SGLT2 gene expression in rat a-cells, b-cells, pancreatic islets, and kidney (K) normalized to Rplp0 (n ¼ 3 for islets, a-cells,
and b-cells; n ¼ 1 for K). (DeE) Insulin (Ins) and glucagon (Gcg) gene expression in mouse FAC-sorted a- and b-cells and pancreatic islets normalized to Gapdh. (FeI) SGLT1
(Slc5a1), SGLT2 (Slc5a2), GLUT1 (Slc2a1), and GLUT2 (Slc2a2) gene expression in mouse a-cells, b-cells, pancreatic islets, gut (G), and kidney (K) normalized to Tbp (n ¼ 3 for
islets, a-cells, and b-cells; n ¼ 4 for G and K). (J-K) Insulin (INS) and glucagon (GCG) gene expression in human FAC-sorted a-and b-cells and pancreatic islets normalized to actin
(ACTB). (L-O) SGLT1 (SLC5A1), SGLT2 (SLC5A2), GLUT1 (SLC2A1), and GLUT2 (SLC2A2) gene expression in human a-cells, b-cells, pancreatic islets, gut (G), and kidney (K)
normalized to actin (ACTB) (n ¼ 4 for islets, a-cells, and b-cells; n ¼ 1 for G; n ¼ 2 for K). All the graphs show individual data and means  SE. Genes with Ct values above 38 for
rats and 40 for mice and humans were considered non-detected (ND).detected in the vast majority of human a-, b-, or d-cells. We searched
for the presence of SGLT2 protein in islet cells by conducting immu-
nodetections with an antibody raised against a 46 amino acid
sequence of SGLT2 that shares only 45% homology to SGLT1. This
antibody produced a strong labeling in proximal tubules in the kidney,
but did not stain any cells in pancreatic sections including 587 human
and 463 rodent islets. In summary, these data do not support theMOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. This is an open a
www.molecularmetabolism.compresence of SGLT2 mRNA or protein at levels of functional relevance in
a-, b-, or d-cells as reported by others [19,21,25].
4.3. Gliflozins do not directly affect glucagon and insulin secretion
or glucagon gene expression
To evaluate if gliflozins directly control hormone secretion from islets,
we tested their effects on glucagon and insulin secretion from isolatedccess article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). 9
Figure 6: Human islet cells express various glucose transporters but almost no SGLT2. (AeB) Single-cell RNA-Seq expression analysis of various glucose transporters in
pancreatic a-, b-, and d-cells from male and female donors from Enge et al. (A [31]) and diabetic and healthy donors from Segerstolpe et al. (B [32]) in transcripts per million
(TPM). A pseudocount of 0.1 was added to the actual TPM values before plotting. Results are shown as boxes and whiskers (10e90% percentile). (CeD) Percentage of cells
expressing SGLT1 and SGLT2 at different expression levels in Enge’s (A) and Segerstolpe’s (B) data.
Original Articlerat or human islets and the in situ perfused mouse pancreas. We used
concentrations well above the IC50 of gliflozins for SGLT2 and the
drugs’ therapeutic Cmax. The IC50 of empagliflozin, dapagliflozin, and
sotagliflozin for hSGLT2/mSGLT2 were 3.1/1.9 nM [33,44,45],
1.2/2.3 nM [33], and 1.8/0.6 nM [46,47], respectively. The plasma
Cmax in humans is 500e700 nM for 25 mg empagliflozin/day [42],
w400 nM for 10 mg dapagliflozin/day [41], andw500 nM for 300 mg
sotagliflozin/day [41]. As all gliflozins strongly bind to plasma proteins
(86% for empagliflozin [48], 91% for dapagliflozin [41,49], and 98%
for sotagliflozin [50]), the free plasma Cmax of the gliflozins does not
exceed 100 nM (700 nM x 0.14 ¼ 98 nM for empagliflozin, 400 nM x
0.09 ¼ 36 nM for dapagliflozin, and 500 nM x 0.02 ¼ 10 nM for10 MOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. Tsotagliflozin), which are, for all, at least 5 times more than their
respective IC50 for SGLT2. The minimal gliflozin concentration that we
used was 1 mM. As we used a medium that contained at least 50 times
lower protein concentration than plasma, it was expected that the free
gliflozin concentrations in our test conditions were above 500 nM, that
is, at least 5 times higher than their free plasma Cmax when used at
therapeutic doses and 150 times higher than their IC50 for SGLT2.
However, even at these supratherapeutic concentrations, we did not
see any significant effect of gliflozins on glucagon and insulin secretion
from islets or perfused pancreas of the three species tested.
We did not test the effect of gliflozins on somatostatin secretion
because our results did not support the possibility that the gliflozinshis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 7: SGLT2 protein is highly expressed in the kidney but undetectable in islet cells. (A) qPCR of SGLT2 gene expression in HEK293 cells expressing (HEK293-hSGLT2)
or not SGLT2, and in human kidney normalized to RPLP0 (n ¼ 2 for HEK cells and n ¼ 1 for kidney). It shows that naïve HEK293 cells do not express significant levels of SGLT2
compared to HEK293-hSGLT2 and the kidney. (B) Uptake of 14C-a-methyl-D-glucopyranoside (14C-AMG) in HEK293 cells expressing (HEK293-hSGLT2) or not SGLT2. The left panel
shows that only HEK293-hSGLT2 uptakes 14C-aMG and that this uptake is fully prevented by empagliflozin and phlorizin. The right panel shows that, as expected for SGLT, this
uptake is Naþ-dependent because it was prevented by replacement of Naþ by choline. Data are means  SE of 4 repetitions. (C) Validation of the anti-SGLT2 antibody by Western
blotting. Membranes of HEK293 cells expressing (HEK293-hSGLT2, bands 3 and 4) or not (bands 1 and 2) SGLT2, human kidney (bands 5 and 6), and islets (band 7) were
pretreated or not with PNGaseF (a deglycosylation enzyme) for 1 h at 37 C before being processed for Western blotting using the anti-SGLT2 antibody. As expected, PNGaseF
removed all glycosylation residues on SGLT2 and induced a shift in the molecular weight. Loading of the gel was controlled by Western blotting for GAPDH. Although the loading of
islet extract exceeded that of control tissues, no SGLT2 band was detected in the islets. The blotting is representative of 7 repetitions for HEK293/HEK293-hSGLT2 cells þ/
PNGaseF, 5 repetitions for kidney þ/ PNGaseF, and 1 blot for islets. (D) Immunodetection of SGLT2 on HEK293 cells expressing (HEK293-hSGLT2 cells) or not SGLT2. SGLT2
immunolabeling was restricted to the plasma membrane of HEK293-SGLT2 cells, while no signal was observed in normal HEK293 cells that were visualized by labeling their nuclei
in blue via DAPI. (E) Immunodetection of SGLT2 in human, rat, and mouse kidney sections shows the expected labeling in proximal tubules. (F) Human, rat, and mouse pancreatic
sections were processed for multiplex immunolabeling of insulin, glucagon, somatostatin, and SGLT2 on the same sections. No SGLT2 signal was detected in pancreatic sections
containing b-cells (insulin), a-cells (glucagon), and d-cells (somatostatin). Nuclei visualized on merged images were labeled with DAPI. Images are representative of 587 human,
305 rat, and 158 mouse islets.
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Figure 8: Empagliflozin and dapagliflozin do not modulate glucagon gene expression in human or rat islets. Glucagon mRNA expression (normalized to Rplp0/RPLP0) in rat
and human pancreatic islets treated with empagliflozin (10 mM) or dapagliflozin (10 mM) in the presence of 11 or 25 mM (rat islets) or 5 or 15 mM of glucose (human islets) as
indicated (n ¼ 6). All the graphs show individual data and means  SE. Groups were not significantly different, as tested by ordinary one-way ANOVA followed by Tukey’s multiple
comparison.
Original Articlemight indirectly control islet hormone secretion, as suggested by
others [25]. However, others failed to observe an effect of dapagliflozin
on somatostatin release [17].
It has been suggested that canagliflozin, a gliflozin with a weak inhib-
itory effect on SGLT1, stimulates glucagon release by targeting SGLT1 in
a-cells [23]. Although our gene expression analyses support the
expression of SGLT1 in human a-cells, we did not observe any effect of
1 mM sotagliflozin, a dual SGLT1/2 inhibitor, on glucagon secretion of
human islets. This concentration far exceeds the IC50 of the drug for
hSGLT1 (36 nM) [46]. This lack of effect was surprising because it was
expected that the characteristics of SGLT1 (cotransport of glucose with
2 Naþ and Km of 2 mM [51]) help to concentrate glucose inside the cell
and that SGLT1 inhibition would affect glucose fluxes across the plasma
membrane. However, given the relatively low expression of SGLT1 in
a-cells (vs the gut), it is possible that other glucose transporters, such
as GLUT1 or GLUT11, which have a high affinity for glucose, are
expressed at the plasma membrane and are present in human a-cells
[18,31,32], keeping glucose flux unaltered in our experimental condi-
tions when SGLT1 was inhibited. It is also unknown whether the SGLT1
transcript in a-cells generates a functional protein. In that context, it
would be very surprising to see an Naþ-dependent glucose transport in
a-cells that are, at first sight, not polarized, whereas most of the SGLTs
are expressed in polarized epithelia of specific organs, such as the gut or
the kidney, to actively take up glucose against its concentration
gradient. Moreover, it is questionable why the a-cell, which needs to
adapt its secretion rate to the external glucose concentration, would use
a transporter that concentrates glucose to intracellular levels that do not
reflect the extracellular levels.
It has also been suggested that SGLT2i stimulate glucagon gene
expression and that this could contribute to hyperglucagonemia [19].
However, we did not detect any effect of 10 mM empagliflozin or dapa-
gliflozin on glucagon gene expression in rat and human islets.
Discrepancies between previously published studies have sometimes
been attributed to differences between the types and concentrations of12 MOLECULAR METABOLISM 42 (2020) 101071  2020 The Authors. Published by Elsevier GmbH. Tthe gliflozin used, species (mouse, rat, or human), cell types (primary
cells or cell lines), experimental models (isolated islets, perfused
pancreas, and in vivo models), conditions (glucose concentration or
other agents), techniques/methods (antibodies or type of gene
expression analysis), and, more recently, inter-individual heterogeneity
[21]. However, one strength of our study is that the experiments were
conducted on three different species using multiple approaches and all
of our findings converged to the same conclusion.
5. CONCLUSION
Our study confirms observations that gliflozins increase the plasma
glucagon/insulin ratio, at least in the fasted state, and provides strong
evidence that this effect does not result from a direct action on islets.
We therefore propose that the SGLT2i-induced increase in glucago-
nemia is a physiological metabolic adaptation to counteract the
glucose-lowering effect of the drugs. The increase in energy intake
upon SGLT2 inhibition also points in a similar direction, whereby a
negative energy balance has to be counteracted by increased gluco-
neogenesis and energy intake to re-establish homeostasis.
Of note, while the SGLT2i-induced increase in the glucagon/insulin
ratio likely contributes to enhanced EGP, it is probably not the only
mechanism. This is supported by a recent study showing increased
dapagliflozin-induced EGP in humans in conditions in which glucagon
and insulin secretions were clamped at basal levels by somatostatin
[52]. There is also an ingrained belief that glucagon exerts strong
ketogenic activities, particularly during fasting and insulinopenic
conditions. Hence, a strong increase in the plasma glucagon/insulin
ratio has often been considered a major cause of diabetic ketoacidosis.
However, the implication of glucagon in ketosis needs to be carefully
reevaluated, since a recent study reported that neither fasting nor
SGLT2i-induced ketosis are altered by interruption of glucagon
signaling in mice unless there is a complete loss of insulin signaling
[14]. Another study suggested that the SGLT2i-induced increasedhis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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incidence of ketoacidosis is independent from hyperglucagonemia but
results, in an insulinopenia setting, from increased plasma catechol-
amine and corticosterone concentrations secondary to volume deple-
tion [11]. Our data, together with these considerations, should temper
the concerns that glucagon is a major aggravating cause of EGP and
ketoacidosis when using SGLT2i.
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